Skip to main content

BASES MOLECULARES DE LA VIRULENCIA DE CORONAVIRUS RESPIRATORIOS HUMANOS Y DISEÑO DE VACUNAS Y ESTRATEGIAS ANTIVIRALES PARA PROTEGER A PACIENTES JOVENES Y MAYORES

BIO2016-75549-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Recombinant Chimeric Transmissible Gastroenteritis Virus (TGEV)—Porcine Epidemic Diarrhea Virus (PEDV) Virus Provides Protection against Virulent PEDV

  • Pascual-Iglesias, Alejandro
  • Sánchez, Carlos M.
  • Penzes, Zoltan
  • Solá Gurpegui, Isabel
  • Enjuanes Sánchez, Luis
  • Zúñiga Lucas, Sonia
Porcine epidemic diarrhea virus (PEDV) is an enteric coronavirus causing high morbidity and mortality in porcine herds worldwide. Although both inactivated and live attenuated vaccines have been extensively used, the emergence of highly virulent strains and the recurrent outbreaks even in vaccinated farms highlight the need of effective vaccines. Engineering of genetically defined live attenuated vaccines is a rational approach for novel vaccine development. In this line, we engineered an attenuated virus based on the transmissible gastroenteritis virus (TGEV) genome, expressing a chimeric spike protein from a virulent United States (US) PEDV strain. This virus (rTGEV-RS-SPEDV) was attenuated in highly-sensitive five-day-old piglets, as infected animals did not lose weight and none of them died. In addition, the virus caused very minor tissue damage compared with a virulent virus. The rTGEV-RS-SPEDV vaccine candidate was also attenuated in three-week-old animals that were used to evaluate the protection conferred by this virus, compared with the protection induced by infection with a virulent PEDV US strain (PEDV-NVSL). The rTGEV-RS-SPEDV virus protected against challenge with a virulent PEDV strain, reducing challenge virus titers in jejunum and leading to undetectable challenge virus RNA levels in feces. The rTGEV-RS-SPEDV virus induced a humoral immune response specific for PEDV, including neutralizing antibodies. Altogether, the data indicated that rTGEV-RS-SPEDV is a promising vaccine candidate against virulent PEDV infection, This research was funded by grants from the Government of Spain (BIO2013-42869-R and BIO2016-75549-R AEI/FEDER, UE), Ceva Animal Health, the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), and the U.S. National Institutes of Health (NIH) (2P01AI060699 awarded to L.E. and I.S.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

  • Stalin Raj, V.
  • Okba, Nisreen M. A.
  • Gutierrez-Alvarez, Francisco J.
  • Drabek, Dubravka
  • Dieren, Brenda van
  • Widagdo, W.
  • Lamers, Mart M.
  • Widjaja, Ivy
  • Fernandez-Delgado, Raúl
  • Solá Gurpegui, Isabel
  • Bensaid, Albert
  • Koopmans, Marion P.
  • Segalés, Joaquim
  • Osterhaus, Albert D. M. E.
  • Bosch, Berend Jan
  • Enjuanes Sánchez, Luis
  • Haagmans, Bart L.
Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of spillover events from dromedaries. In contrast to humans, MERS-CoV¿exposed dromedaries develop only very mild infections and exceptionally potent virus-neutralizing antibody responses. These strong antibody responses may be caused by affinity maturation as a result of repeated exposure to the virus or by the fact that dromedaries¿ apart from conventional antibodies¿have relatively unique, heavy chain¿only antibodies (HCAbs)., This study was financed by a grant from the Zoonotic Anticipation and Preparedness Initiative [ZAPI project; Innovative Medicines Initiative (IMI) grant agreement no. 115760], with the assistance and financial support of IMI and the European Commission, and in-kind contributions from European Federation of Pharmaceutical Industries and Associations partners. A part of the study was supported by the European Virus Archive Goes Global project, which received a grant from the European Union Horizon 2020 Framework Program for Research and Innovation (653316) and grants from the Ministry of Science and Innovation of Spain (Bio2016-75549-R AEI/FEDER, UE) and NIH (2PO1AIO6O699)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

  • Widjaja, Ivy
  • Wang, Chengbao
  • Haperen, Rien van
  • Gutierrez-Alvarez, Francisco J.
  • Dieren, Brenda van
  • Okba, Nisreen M. A.
  • Stalin Raj, V.
  • Li, Wentao
  • Fernandez-Delgado, Raúl
  • Grosveld, Frank
  • Kuppeveld, Frank J. M. van
  • Haagmans, Bart L.
  • Enjuanes Sánchez, Luis
  • Drabek, Dubravka
  • Bosch, Berend Jan
The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions., This study was financed by a grant from the IMI-ZAPI (Zoonotic Anticipation and Preparedness Initiative (ZAPI) project; Innovative Medicines Initiative (IMI)) [grant agreement no. 115760], with the assistance and financial support of IMI and the European Commission, and in-kind contributions from European Federation of Pharmaceutical Industries and Associations partners. This study was also partially financed by grants from the Ministry of Science and Innovation of Spain (BIO2016-75549-R AEI/FEDER, UE) and NIH (2PO1AIO6O699). This work was supported by Center for Scientific Review, China Scholarship Council
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology

  • Morales, Lucía
  • Oliveros, Juan C.
  • Fernandez-Delgado, Raúl
  • tenOever, Benjamin Robert
  • Enjuanes Sánchez, Luis
  • Solá Gurpegui, Isabel
Severe acute respiratory syndrome coronavirus (SARS-CoV) causes lethal disease in humans, which is characterized by exacerbated inflammatory response and extensive lung pathology. To address the relevance of small non-coding RNAs in SARS-CoV pathology, we deep sequenced RNAs from the lungs of infected mice and discovered three 18–22 nt small viral RNAs (svRNAs). The three svRNAs were derived from the nsp3 (svRNA-nsp3.1 and -nsp3.2) and N (svRNA-N) genomic regions of SARS-CoV. Biogenesis of CoV svRNAs was RNase III, cell type, and host species independent, but it was dependent on the extent of viral replication. Antagomir-mediated inhibition of svRNA-N significantly reduced in vivo lung pathology and pro-inflammatory cytokine expression. Taken together, these data indicate that svRNAs contribute to SARS-CoV pathogenesis and highlight the potential of svRNA-N antagomirs as antivirals., This work was supported by grants from the Ministry of Science and Innovation of Spain ( BIO2010-16705 , BIO2013-42869-R , and BIO2016-75549-R AEI/FEDER, UE ), the European Zoonoses anticipation and preparedness initiative ZAPI ( IMI_JU_115760 ), and U.S. National Institutes of Health ( NIH ) ( 2P01AI060699 and 0258-3413/HHSN266200700010C ). L.M. received a fellowship from the Ministry of Science an Innovation of Spain ( BIO2010-16705 ) and a contract from ZAPI. R.F.-D received contracts from NIH and ZAPI.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of severe acute respiratory syndrome coronavirus viroporins E, 3a, and 8a in replication and pathogenesis

  • Castaño-Rodríguez, Carlos
  • Honrubia, José M.
  • Gutierrez-Alvarez, Francisco J.
  • DeDiego, Marta L.
  • Nieto-Torres, José L.
  • Jiménez-Guardeño, José Manuel
  • Regla-Nava, José Ángel
  • Fernandez-Delgado, Raúl
  • Verdiá-Báguena, Carmina
  • Queralt-Martín, María
  • Kochan, Grazyna
  • Perlman, Stanley
  • Aguilella, Vicente M.
  • Solá Gurpegui, Isabel
  • Enjuanes Sánchez, Luis
Viroporins are viral proteins with ion channel (IC) activity that play an important role in several processes, including virus replication and pathogenesis. While many coronaviruses (CoVs) encode two viroporins, severe acute respiratory syndrome CoV (SARS-CoV) encodes three: proteins 3a, E, and 8a. Additionally, proteins 3a and E have a PDZ-binding motif (PBM), which can potentially bind over 400 cellular proteins which contain a PDZ domain, making them potentially important for the control of cell function. In the present work, a comparative study of the functional motifs included within the SARS-CoV viroporins was performed, mostly focusing on the roles of the IC and PBM of E and 3a proteins., This work was supported by grants from the Government of Spain (BIO2013-42869-R and BIO2016-75549-R AEI/FEDER, UE), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), and the U.S. National Institutes of Health (NIH) (0258-3413/HHSN266200700010C awarded to L.E., 2P01AI060699 awarded to L.E. and S.P., and R01 AI129269 awarded to S.P.). V.M.A. and M.Q.M. are grateful for the support of the Government of Spain (FIS2013-40473-P and FIS2016-75257-P AEI/FEDER, UE) and Universitat Jaume I (P1.1B2015-28). C.C.R. received a contract from Fundación La Caixa.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Minimum determinants of transmissible gastroenteritis virus enteric tropism are located in the N-terminus of spike protein

  • Sánchez, Carlos M.
  • Pascual-Iglesias, Alejandro
  • Solá Gurpegui, Isabel
  • Zúñiga Lucas, Sonia
  • Enjuanes Sánchez, Luis
Transmissible gastroenteritis virus (TGEV) is an enteric coronavirus causing high morbidity and mortality in porcine herds worldwide, that possesses both enteric and respiratory tropism. The ability to replicate in the enteric tract directly correlates with virulence, as TGEVs with an exclusive respiratory tropism are attenuated. The tissue tropism is determined by spike (S) protein, although the molecular bases for enteric tropism remain to be fully characterized. Both pAPN and sialic acid binding domains (aa 506–655 and 145–155, respectively) are necessary but not sufficient for enteric tract infection. Using a TGEV infectious cDNA and enteric (TGEV-SC11) or respiratory (TGEV-SPTV) isolates, encoding a full-length S protein, a set of chimeric recombinant viruses, with a sequential modification in S protein amino terminus, was engineered. In vivo tropism, either enteric, respiratory or both, was studied by inoculating three-day-old piglets and analyzing viral titers in lung and gut. The data indicated that U655>G change in S gene (S219A in S protein) was required to confer enteric tropism to a respiratory virus that already contains the pAPN and sialic acid binding domains in its S protein. Moreover, an engineered virus containing U655>G and a 6 nt insertion at position 1124 (Y374-T375insND in S protein) was genetically stable after passage in cell cultures, and increased virus titers in gut by 1000-fold. We postulated that the effect of these residues in enteric tropism may be mediated by the modification of both glycosaminoglycan binding and S protein structure., This research was funded by grants from the Government of Spain (BIO2013-42869-R and BIO2016-75549-R AEI/FEDER, UE), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), and the U.S. National Institutes of Health (NIH) (2P01AI060699 awarded to L.E. and I.S.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MERS-CoV 4b protein interferes with the NF-kappaB-dependent innate immune response during infection

  • Cantón, Javier
  • Fehr, Anthony R.
  • Fernandez-Delgado, Raúl
  • Gutierrez-Alvarez, Francisco J.
  • Sánchez-Aparicio, María T.
  • García-Sastre, Adolfo
  • Perlman, Stanley
  • Enjuanes Sánchez, Luis
  • Solá Gurpegui, Isabel
Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel human coronavirus that emerged in 2012, causing severe pneumonia and acute respiratory distress syndrome (ARDS), with a case fatality rate of ~36%. When expressed in isolation, CoV accessory proteins have been shown to interfere with innate antiviral signaling pathways. However, there is limited information on the specific contribution of MERS-CoV accessory protein 4b to the repression of the innate antiviral response in the context of infection. We found that MERS-CoV 4b was required to prevent a robust NF-κB dependent response during infection. In wild-type virus infected cells, 4b localized to the nucleus, while NF-κB was retained in the cytoplasm. In contrast, in the absence of 4b or in the presence of cytoplasmic 4b mutants lacking a nuclear localization signal (NLS), NF-κB was translocated to the nucleus leading to the expression of pro-inflammatory cytokines. This indicates that NF-κB repression required the nuclear import of 4b mediated by a specific NLS. Interestingly, we also found that both in isolation and during infection, 4b interacted with α-karyopherin proteins in an NLS-dependent manner. In particular, 4b had a strong preference for binding karyopherin-α4 (KPNA4), which is known to translocate the NF-κB protein complex into the nucleus. Binding of 4b to KPNA4 during infection inhibited its interaction with NF-κB-p65 subunit. Thereby we propose a model where 4b outcompetes NF-κB for KPNA4 binding and translocation into the nucleus as a mechanism of interference with the NF-κB-mediated innate immune response., This work was supported by grants from the Government of Spain (BIO2013-42869-R and BIO2016-75549-R AEI/FEDER, UE), the European Zoonotic anticipation and preparedness initiative ZAPI (IMI_115760), and U.S. National Institutes of Health (NIH) (contract #0258-3413/ HHSN266200700010C (LE), 2P01 AI060699 (LE and SP), and R01 AI129269 (SP). JC received a contract from the Government of Spain (BIO2013- 42869-R). ARF was supported by institutional NRSA training grant T32-AI007260 and an individual NIH NRSA grant (F32-AI113973).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Canonical and Noncanonical Autophagy as Potential Targets for COVID-19

  • Bello-Pérez, Melissa
  • Solá Gurpegui, Isabel
  • Novoa, Beatriz
  • Klionsky, Daniel J.
  • Falcó, Alberto
The SARS-CoV-2 pandemic necessitates a review of the molecular mechanisms underlying cellular infection by coronaviruses, in order to identify potential therapeutic targets against the associated new disease (COVID-19). Previous studies on its counterparts prove a complex and concomitant interaction between coronaviruses and autophagy. The precise manipulation of this pathway allows these viruses to exploit the autophagy molecular machinery while avoiding its protective apoptotic drift and cellular innate immune responses. In turn, the maneuverability margins of such hijacking appear to be so narrow that the modulation of the autophagy, regardless of whether using inducers or inhibitors (many of which are FDA-approved for the treatment of other diseases), is usually detrimental to viral replication, including SARS-CoV-2. Recent discoveries indicate that these interactions stretch into the still poorly explored noncanonical autophagy pathway, which might play a substantial role in coronavirus replication. Still, some potential therapeutic targets within this pathway, such as RAB9 and its interacting proteins, look promising considering current knowledge. Thus, the combinatory treatment of COVID-19 with drugs a ecting both canonical and noncanonical autophagy pathways may be a turning point in the fight against this and other viral infections, which may also imply beneficial prospects of long-term protection, This research was funded by the FEDER/Spanish Ministry of Science and Innovation – State Agency of Research, grant number RTI2018-101969-J-I00; CSIC and Ministry of Science and Innovation of Spain (BIO2016-75549-R AEI/FEDER, UE; PIE Ref. 202020E079; PIE CSIC Ref. 202020E043), European Commission, H2020-SC1-2019 (Improved Vaccination Strategies for Older Adults, ISOLDA_Ref. 848166) and U.S. National Institutes of Health (NIH) (2P01AI060699, 0258-3413/HHSN266200700010C and GM131919). M.B.-P. received a contract from NIH., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein

  • Wang, Chunyan
  • Haperen, Rien van
  • Gutierrez-Alvarez, Francisco J.
  • Li, Wentao
  • Okba, Nisreen M. A.
  • Albulescu, Irina
  • Widjaja, Ivy
  • Dieren, Brenda van
  • Fernandez-Delgado, Raúl
  • Solá Gurpegui, Isabel
  • Hurdiss, Daniel L.
  • Daramola, Olalekan
  • Grosveld, Frank
  • Kuppeveld, Frank J. M. van
  • Haagmans, Bart L.
  • Enjuanes Sánchez, Luis
  • Drabek, Dubravka
  • Bosch, Berend Jan
The coronavirus spike glycoprotein, located on the virion surface, is the key mediator of cell entry. As such, it is an attractive target for the development of protective antibodies and vaccines. Here we describe two human monoclonal antibodies, 1.6C7 and 28D9, that display a remarkable cross-reactivity against distinct species from three Betacoronavirus subgenera, capable of binding the spike proteins of SARS-CoV and SARS-CoV-2, MERS-CoV and the endemic human coronavirus HCoV-OC43. Both antibodies, derived from immunized transgenic mice carrying a human immunoglobulin repertoire, blocked MERS-CoV infection in cells, whereas 28D9 also showed weak cross-neutralizing potential against HCoV-OC43, SARS-CoV and SARS-CoV-2 in a neutralization-sensitive virus pseudotyping system, but not against authentic virus. Both cross-reactive monoclonal antibodies were found to target the stem helix in the spike protein S2 fusion subunit which, in the prefusion conformation of trimeric spike, forms a surface exposed membrane-proximal helical bundle, that is antibody-accessible. We demonstrate that administration of these antibodies in mice protects from a lethal MERS-CoV challenge in both prophylactic and/or therapeutic models. Collectively, these antibodies delineate a conserved, immunogenic and vulnerabe site on the spike protein which spurs the development of broad-range diagnostic, preventive and therapeutic measures against coronaviruses., The project was co-financed by a grant from the Zoonotic Anticipation and Preparedness Initiative [ZAPI project; Innovative Medicines Initiative (IMI) grant agreement no. 115760], with the assistance and financial support of IMI and the European Commission, and in-kind contributions from European Federation of Pharmaceutical Industries and Associations partners. The collaboration project is cofunded by the PPP Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. This study was also partially financed by grants from the Ministry of Science and Innovation of Spain (BIO2016-75549-R AEI/FEDER, UE) and NIH (2PO1AIO6O699). The mice used to generate the mAbs produced in this study were provided by Harbour Antibodies BV, a daughter company of Harbour Biomed (http://www.harbourbiomed.com). Chunyan Wang was supported by a grant from the China Scholarship Council., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Contribution of Host miRNA-223-3p to SARS-CoV-Induced Lung Inflammatory Pathology

  • Morales, Lucía
  • Oliveros, Juan C.
  • Enjuanes Sánchez, Luis
  • Solá Gurpegui, Isabel
Severe acute respiratory syndrome coronavirus (SARS-CoV) and the closely related SARS-CoV-2 are emergent highly pathogenic human respiratory viruses causing acute lethal disease associated with lung damage and dysregulated inflammatory responses. SARS-CoV envelope protein (E) is a virulence factor involved in the activation of various inflammatory pathways. Here, we study the contribution of host miRNAs to the virulence mediated by E protein. Small RNAseq analysis of infected mouse lungs identified miRNA-223 as a potential regulator of pulmonary inflammation, since it was significantly increased in SARS-CoV-WT virulent infection compared to the attenuated SARS-CoV-DE infection. In vivo inhibition of miRNA-223-3p increased mRNA levels of pro-inflammatory cytokines and NLRP3 inflammasome, suggesting that during lung infection, miRNA-223 might contribute to restrict an excessive inflammatory response. Interestingly, miRNA-223-3p inhibition also increased the levels of the CFTR transporter, which is involved in edema resolution and was significantly downregulated in the lungs of mice infected with the virulent SARS-CoV-WT virus. At the histopathological level, a decrease in the pulmonary edema was observed when miR-223-3p was inhibited, suggesting that miRNA-223-3p was involved in the regulation of the SARS-CoVinduced inflammatory pathology. These results indicate that miRNA-223 participates in the regulation of E protein-mediated inflammatory response during SARS-CoV infection by targeting different host mRNAs involved in the pulmonary inflammation, and identify miRNA-223 as a potential therapeutic target in SARS-CoV infection. IMPORTANCE The SARS-CoV-2 pandemic has emphasized the need to understand the mechanisms of severe lung inflammatory pathology caused by human deadly coronaviruses in order to design new antiviral therapies. Here, we identify miRNA-223-3p as a host miRNA involved in the regulation of lung inflammatory response mediated by envelope (E) protein during SARS-CoV infection. miRNAs downregulate the expression of cellular mRNAs and participate in complex networks of mRNA–miRNA interactions that regulate cellular processes. The inhibition of miRNA-223 in infected mice by intranasal administration of antisense RNAs led to changes in the expression of host factors involved in inflammation (cytokines, chemokines, and NLRP3 inflammasome) and in the resolution of lung edema ion transporter CFTR. These results confirmed the contribution of miRNA-223 to the regulation of SARS-CoV-induced pathogenic processes and support the therapeutic potential of inhibiting miRNAs during coronavirus infection using RNA interference approaches., This work was supported by grants from the Government of Spain (BIO2016-75549-R; PID2019-107001RBI00 AEI/FEDER, UE; SEV 2017-0712 and PIE_INTRAMURAL_LINEA 1-202020E079), CSIC (PIE_INTRAMURAL -202020E043), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), the European Commission (H2020-SC1-2019, ISOLDA Project No. 848166-2), and the U.S. National Institutes of Health (NIH) (2P01AI060699). L.M. received a fellowship from the Ministry of Science an Innovation of Spain (BIO2010-16705) and a contract from ZAPI., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

MERS-CoV ORF4b is a virulence factor involved in the inflammatory pathology induced in the lungs of mice

  • Bello-Pérez, Melissa
  • Hurtado-Tamayo, Jesús
  • Requena-Platek, Ricardo
  • Cantón, Javier
  • Sánchez-Cordón, Pedro J.
  • Fernandez-Delgado, Raúl
  • Enjuanes Sánchez, Luis
  • Solá Gurpegui, Isabel
23 Pág. Centro de Investigación en Sanidad Animal (CISA), No vaccines or specific antiviral drugs are authorized against Middle East respiratory syndrome coronavirus (MERS-CoV) despite its high mortality rate and prevalence in dromedary camels. Since 2012, MERS-CoV has been causing sporadic zoonotic infections in humans, which poses a risk of genetic evolution to become a pandemic virus. MERS-CoV genome encodes five accessory proteins, 3, 4a, 4b, 5 and 8b for which limited information is available in the context of infection. This work describes 4b as a virulence factor in vivo, since the deletion mutant of a mouse-adapted MERS-CoV-Δ4b (MERS-CoV-MA-Δ4b) was completely attenuated in a humanized DPP4 knock-in mouse model, resulting in no mortality. Attenuation in the absence of 4b was associated with a significant reduction in lung pathology and chemokine expression levels at 4 and 6 days post-infection, suggesting that 4b contributed to the induction of lung inflammatory pathology. The accumulation of 4b in the nucleus in vivo was not relevant to virulence, since deletion of its nuclear localization signal led to 100% mortality. Interestingly, the presence of 4b protein was found to regulate autophagy in the lungs of mice, leading to upregulation of BECN1, ATG3 and LC3A mRNA. Further analysis in MRC-5 cell line showed that, in the context of infection, MERS-CoV-MA 4b inhibited autophagy, as confirmed by the increase of p62 and the decrease of ULK1 protein levels, either by direct or indirect mechanisms. Together, these results correlated autophagy activation in the absence of 4b with downregulation of a pathogenic inflammatory response, thus contributing to attenuation of MERS-CoV-MA-Δ4b., This work was supported by grants from the Government of Spain (BIO2016-75549-R; PID2019-107001RB-I00 AEI/FEDER, UE; SEV 2017-0712 and PIE_INTRAMURAL_LINEA 1-202020E079), CSIC (PIE_INTRAMURAL -202020E043), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), the European Commission (H2020-SC1-2019, ISOLDA Project No. 848166-2), and the U.S. National Institutes of Health (NIH) (2P01AI060699 to I.S.). J.C. and J.H-T: received fellowships from the Ministry of Science an Innovation of Spain (BIO2013- 42869-R and PID2019-107001RB-I00 AEI/FEDER). M.B-P. received a contract from ISOLDA_848166 H2020-SC1-2019-Two-Stage-RTD.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SARS-CoV-2-Mediated Lung Edema and Replication Are Diminished by Cystic Fibrosis Transmembrane Conductance Regulator Modulators

  • Honrubia, José M.
  • Gutierrez-Álvarez, Javier
  • Sanz-Bravo, Alejandro
  • González-Miranda, Ezequiel
  • Muñoz-Santos, Diego
  • Castaño-Rodriguez, Carlos
  • Wang, Li
  • Villarejo-Torres, Marta
  • Ripoll-Gómez, Jorge
  • Esteban, Ana
  • Fernandez-Delgado, Raúl
  • Sánchez-Cordón, Pedro J.
  • Oliveros, Juan C.
  • Perlman, Stanley
  • McCray, Paul B
  • Solá Gurpegui, Isabel
  • Enjuanes Sánchez, Luis
20 Pág., Coronaviruses (CoVs) of genera α, β, γ, and δ encode proteins that have a PDZ-binding motif (PBM) consisting of the last four residues of the envelope (E) protein (PBM core). PBMs may bind over 400 cellular proteins containing PDZ domains (an acronym formed by the combination of the first letter of the names of the three first proteins where this domain was identified), making them relevant for the control of cell function. Three highly pathogenic human CoVs have been identified to date: severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2. The PBMs of the three CoVs were virulence factors. SARS-CoV mutants in which the E protein PBM core was replaced by the E protein PBM core from virulent or attenuated CoVs were constructed. These mutants showed a gradient of virulence, depending on whether the alternative PBM core introduced was derived from a virulent or an attenuated CoV. Gene expression patterns in the lungs of mice infected with SARS-CoVs encoding each of the different PBMs were analyzed by RNA sequencing of infected lung tissues. E protein PBM of SARS-CoV and SARS-CoV-2 dysregulated gene expression related to ion transport and cell homeostasis. Decreased expression of cystic fibrosis transmembrane conductance regulator (CFTR) mRNA, essential for alveolar edema resolution, was shown. Reduced CFTR mRNA levels were associated with edema accumulation in the alveoli of mice infected with SARS-CoV and SARS-CoV-2. Compounds that increased CFTR expression and activity, significantly reduced SARS-CoV-2 growth in cultured cells and protected against mouse infection, suggesting that E protein virulence is mediated by a decreased CFTR expression. IMPORTANCE Three highly pathogenic human CoVs have been identified: SARS-CoV, MERS-CoV, and SARS-CoV-2. The E protein PBMs of these three CoVs were virulence factors. Gene expression patterns associated with the different PBM motifs in the lungs of infected mice were analyzed by deep sequencing. E protein PBM motif of SARS-CoV and SARS-CoV-2 dysregulated the expression of genes related to ion transport and cell homeostasis. A decrease in the mRNA expression of the cystic fibrosis transmembrane conductance regulator (CFTR), which is essential for edema resolution, was observed. The reduction of CFTR mRNA levels was associated with edema accumulation in the lungs of mice infected with SARS-CoV-2. Compounds that increased the expression and activity of CFTR drastically reduced the production of SARS-CoV-2 and protected against its infection in a mice model. These results allowed the identification of cellular targets for the selection of antivirals., This work was supported by grants from the Government of Spain (BIO2016-75549-R; PID2019-107001RB-I00 AEI/FEDER, UE; SEV 2017-0712 and PIE_INTRAMURAL_LINEA 1- 202020E079), CSIC (PIE_INTRAMURAL-202020E043), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), the European Commission (H2020-SC1- 2019, ISOLDA Project No. 848166-2), and the U.S. National Institutes of Health (NIH) (2P01AI060699). J.M.H. received a contract from Comunidad de Madrid (Y2020/BIO-6576, COVID-PREclinical-MODels-CM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. In vivo experiments were performed at INIA-CISA (Madrid, Spain), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SARS-CoV-2 ORF8 accessory protein is a virulence factor

  • Bello-Pérez, Melissa
  • Hurtado-Tamayo, Jesús
  • Mykytyn, Anna Z.
  • Lamers, Mart M.
  • Requena-Platek, Ricardo
  • Schipper, D.
  • Muñoz-Santos, Diego
  • Ripoll-Gómez, Jorge
  • Esteban, Ana
  • Sánchez-Cordón, Pedro J.
  • Enjuanes Sánchez, Luis
  • Haagmans, Bart L.
  • Solá Gurpegui, Isabel
The relevance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ORF8 in the pathogenesis of COVID-19 is unclear. Virus natural isolates with deletions in ORF8 were associated with wild milder disease, suggesting that ORF8 might contribute to SARS-CoV-2 virulence. This manuscript shows that ORF8 is involved in inflammation and in the activation of macrophages in two experimental systems: humanized K18-hACE2 transgenic mice and organoid-derived human airway cells. These results identify ORF8 protein as a potential target for COVID-19 therapies., This work was supported by grants from the Government of Spain (BIO2016-75549-R; PID2019-107001RB-I00 AEI/FEDER, UE; SEV 2017-0712 and PIE_INTRAMURAL_LINEA 1–202020E079), CSIC (PIE_INTRAMURAL -202020E043), the European Zoonotic Anticipation and Preparedness Initiative (ZAPI) (IMI_JU_115760), the European Commission (H2020-SC1-2019, ISOLDA Project No. 848166-2), the U.S. National Institutes of Health (NIH) (2P01AI060699), and the Netherlands Organization for Health Research and Development (project no. 10430012010004). M.B.-P. received a contract from H2020-SC1-2019 and a Jose Castillejo fellowship for PhDs' mobility. J.H.-T. received a fellowship from PID2019-107001RB-I00 AEI/FEDER, UE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

  • Stalin Raj, V.|||0000-0003-2250-8481
  • Okba, Nisreen M. A.|||0000-0002-2394-1079
  • Gutierrez-Alvarez, Javier|||0000-0003-0690-9496
  • Drabek, Dubravka
  • van Dieren, Brenda|||0000-0001-7665-683X
  • Widagdo, Widagdo
  • Lamers, Mart M.
  • Widjaja, Ivy
  • Fernandez-Delgado, Raul|||0000-0001-7411-9010
  • Sola, Isabel|||0000-0002-5704-1917
  • Bensaid, Albert|||0000-0001-6493-3756
  • Koopmans, Marion P.G|||0000-0002-5204-2312
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Osterhaus, Albert D. M. E.
  • Bosch, Berend-Jan|||0000-0002-3864-232X
  • Enjuanes, Luis|||0000-0002-0854-0226
  • Haagmans, Bart L.|||0000-0001-6221-2015
Dromedary camel heavy chain-only antibodies may provide novel intervention strategies against MERS coronavirus. Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of spillover events from dromedaries. In contrast to humans, MERS-CoV-exposed dromedaries develop only very mild infections and exceptionally potent virus-neutralizing antibody responses. These strong antibody responses may be caused by affinity maturation as a result of repeated exposure to the virus or by the fact that dromedaries-apart from conventional antibodies-have relatively unique, heavy chain-only antibodies (HCAbs). These HCAbs are devoid of light chains and have long complementarity-determining regions with unique epitope binding properties, allowing them to recognize and bind with high affinity to epitopes not recognized by conventional antibodies. Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone marrow of MERS-CoV-infected dromedaries, we identified several MERS-CoV-specific VHHs or nanobodies. In vitro, these VHHs efficiently blocked virus entry at picomolar concentrations. The selected VHHs bind with exceptionally high affinity to the receptor binding domain of the viral spike protein. Furthermore, camel/human chimeric HCAbs-composed of the camel VHH linked to a human Fc domain lacking the CH1 exon-had an extended half-life in the serum and protected mice against a lethal MERS-CoV challenge. HCAbs represent a promising alternative strategy to develop novel interventions not only for MERS-CoV but also for other emerging pathogens.